A Study of Breastfeeding in Buprenorphine Maintained Women

Opioid Dependency Clinical Trial

Official title:

Lactation Among Buprenorphine Maintained Women: A Pilot Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01806389
• Other study ID #: NA_00080884
• Status: Completed
• Phase: N/A
• First received: February 20, 2013
• Last updated: February 29, 2016
• Start date: February 2013
• Est. completion date: February 2016

Study information

• Verified date: February 2013
• Source: Johns Hopkins University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

Goals: The overarching goals for this proposed research are to provide pilot data for a study to inform the FDA regarding the safety of breastfeeding infants of mothers on buprenorphine maintenance and to develop guidelines for the practitioner treating buprenorphine maintained women who wish to breastfeed.

Background: There is an increase in the prevalence of illicit opiate use among women of childbearing age. Recently, a large multisite study has suggested buprenorphine as an alternative to methadone for use in this population. As a consequence, buprenorphine is likely to be delivered to larger populations of pregnant and post-partum women. The population of prenatally opioid-exposed neonates is a particularly vulnerable population. Advances in neuroscience, molecular biology and epigenetics indicate that greater attention should be given to strategies that prevent, reduce, or mitigate the consequences of significant adversity on the developing brain. Breast milk and breastfeeding offer significant health and other benefits that are particularly salient for this group. Today, there is a near complete lack of information regarding the safety of buprenorphine maintenance and lactation, making it unlikely that providers will endorse or mothers will adopt this practice.

Methods: Five pregnant buprenorphine maintained breastfeeding women and their neonates will be enrolled. Subjects will selected by buprenorphine maintenance in the postpartum period and enrollment in a parent protocol and by decision to breast feed their infants. Subject will provide breast milk at times of peak maternal buprenorphine levels on days 2, 3, 4, 14 and 30 after delivery to determine buprenorphine and norbuprenorphine concentrations. Subjects will also provide plasma at times of peak buprenorphine levels for determination of buprenorphine and norbuprenorphine concentrations on the same days. Concentrations of buprenorphine and norbuprenorphine in the plasma of infants will be determined on approximately day 14 of life. The relationship between maternal dose, maternal and infant plasma concentrations, and breast milk concentrations of buprenorphine and norbuprenorphine will be determined, and ingestible infant dose calculated.

Description:

This study recruits participants from a funded trial evaluating fetal neurobehavior and maternal physiology among a population of opioid dependent and buprenorphine maintained pregnant women. Those women electing to breastfeed will be approached for participation in this study at 36 weeks of gestation.

Study Procedures Study participants will have urine toxicology testing for the following drug classes/cut off values: cocaine/300 ng/mL; methamphetamines/1000ng/mL; methadone/300ng/mL; MDMA/500 ng/mL; MOP/300 ng/mL; oxycodone/100 ng/mL; PCP/25 ng/mL; benzodiazepines/300ng/mL; buprenorphine/10 ng/mL; marijuana/50ng/mL weekly as part of study procedures in addition to weekly random urine toxicology screening provided at CAP for the study period of 36 weeks until delivery. To ensure that participants are not using illicit substances or abusing licit substances and are candidates for the institution and continuation of breastfeeding, subjects will continue to provide urine toxicology testing as above for the period of time from delivery to day 30 postpartum. Subjects noted to be doing so will be discharged from the protocol and referred to their substance abuse treatment counselor for appropriate consequences.

Data collection protocol: Upon delivery, the nursing staff at the hospital of delivery will contact study staff for initiation of study procedures. Women will have plasma and breast milk samples obtained by study personnel on days 2, 3, 4, 14 and 30 at times of peak (2 ½ hours after sublingual dosing) maternal buprenorphine levels. Infant weight will be collected on these days. Days of data collection will be determined by the, 2nd, 3rd, 4th 24 hour periods after birth of the infant. The 14th, and 30th day data collections will occur on the weekday nearest the 24 hour period on those days. Infant NICU Network Neurobehavioral Scale scores on days 3, 14 and 30 and infant NAS scores as below are collected as part of the parent protocol and data abstracted for this protocol.

Maternal plasma: Using 3mL vacutainer green-top collection tubes, 3 cc of blood will be collected via venupuncture by one of two study RNs, one responsible for inpatient specimen collection (i.e. while the mother and infant are hospitalized after delivery) and one responsible for outpatient specimen collection (after hospital discharge). Blood samples will be collected on ice and within two hours, cold centrifuged to harvest the plasma. Plasma will be stored in polypropylene tubes and stored at -20°C. Plasma will be collected at times of peak maternal buprenorphine levels on days 2, 3, 4, 14 (approximately) and 30 (approximately) after infant delivery.

Breast milk: Breast milk samples will be collected after the infant has completed feeding from the same breast via electric pump and consist of approximately 5 cc of breast milk at time of peak maternal buprenorphine levels on days 2,3,4, 14 and 30 after infant delivery. Breast milk will be stored at -20°C within two hours of collection.

Analysis of breast milk and plasma samples: Plasma and breast milk samples will be analyzed by the Chemistry and Drug Metabolism Section of the Intramural Research Program of the National Institute on Drug Abuse, National Institutes of Health in Baltimore, Maryland under the direction of Dr. Marilyn A. Huestis.

Infant plasma: 1cc of infant blood will be taken by heel stick on the weekday nearest day 14 of life. The 14 day blood sample will be coincident with a routine infant blood test (PKU testing) when possible. Blood samples will be collected on ice and within two hours, cold centrifuged to remove plasma. Plasma will be stored in polypropylene tubes and stored at -20°C until analysis.

Other infant data: Infant weight will be obtained at each data collection point (i.e. days 2,3,4, 14 and 30).

Other maternal data: Maternal compliance to drug treatment will be abstracted from daily treatment records. Poor compliance to treatment will be determined on an individual basis via discussion with the subject's counselor, but in general compliance will be determined by attendance to daily therapy at CAP with no unexcused or unexplained absence from treatment in the 30 days subsequent to delivery.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: February 2016
• Est. primary completion date: February 2016
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 41 Years

Eligibility

Inclusion Criteria:

1. Age 18-41 years

2. Opioid dependent per DSMIVR criteria, buprenorphine maintained, enrolled in parent study.

3. Delivery at 37 weeks of gestation or later

4. Breast feeding in the first month of life

Exclusion Criteria:

1. Concurrent Axis I diagnosis, or the presence of a serious psychiatric illness that would preclude informed consent

2. Major congenital malformation or minor congenital malformation that would impair the infant's ability to feed (i.e. Pierre-Robin syndrome, cleft palate)

3. Delivery at an outside institution unaffiliated with this protocol

4. Failure to leave specimens as per protocol

5. Infant medical complications that impair the ability to feed after delivery (i.e. respiratory concerns such as meconium aspiration, perinatal asphyxia, etc. These will be individually determined on a case-by-case basis)

6. Any detected maternal medical condition making lactation inadvisable, i.e. newly diagnosed HIV infection or requirement for medication not compatible with breastfeeding.

7. Infants with other medical conditions that would make study participation impossible, i.e. nonviable neonates, neonates with uncertain viability.

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Opioid Dependency

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Johns Hopkins University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in maternal plasma concentrations of buprenorphine	Maternal plasma will be obtained at the time of peak buprenorphine levels on days 2,3,4,14 and 30	Days 2,3,4,14 and 30 after delivery	No
Primary	Change in maternal breast milk concentrations of buprenorphine	Breast milk will be obtained on these days at the time of peak plasma levels of buprenoprhine	Days 2,3,4,14 and 30 after delivery	No
Primary	Infant plasma concentrations of buprenorphine	Infant plasma will be obtaqined on day 14 of life	Day 14 of life	No